Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Predictors of survival in patients with HER2+ metastatic breast cancer (MBC) treated with trastuzumab.

Predictors of survival in patients with HER2+ metastatic breast cancer (MBC) treated with trastuzumab. J Clin Oncol. 2011 May 20; 29(15_suppl):e11100.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.